Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fluticasone furoate (FF) Dry Powder Inhaler; Drug: Fluticasone propionate (FP) Dry Powder Inhaler; Drug: Budesonide (BUD) Turbuhaler; Drug: Placebo (ELLIPTA or DISKUS)
Sponsor: GlaxoSmithKline
Not yet recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Device: ELLIPTA DPI; Device: GSK MDI; Device: AZ MDI
Sponsor: GlaxoSmithKline
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Sirukumab; Drug: Placebo; Drug: Rescue medication
Sponsor: GlaxoSmithKline
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Lung Disease News |
Severe Asthma Reduced in Phase 3 Benralizumab Tests
Lung Disease News AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound was well … |
View full post on asthma – Google News
Wall Street Journal |
AstraZeneca's Severe Asthma Drug Positive in Phase III
Zacks.com These randomized, double-blind, parallel-group, placebo-controlled studies evaluated the safety and efficacy of benralizumab as an add-on therapy in the treatment of severe uncontrolled asthma with eosinophilic inflammation in patients aged 12 years … AstraZeneca's Asthma Drug Shows Positive Results AstraZeneca set to go head to head against GSK with asthma drug AstraZeneca asthma drug hits goal, to enter competitive market |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Fluticasone furoate (FF) (100 mcg); Drug: Vilanterol (VI) (25 mcg); Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified March 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in …
Benzinga Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate-to-severe asthma, who are uncontrolled despite treatment with … |
View full post on asthma – Google News
|
Boehringer Presents New Phase III Data for Asthma Therapy Tiotropium
Lung Disease News Boehringer Ingelheim Pharmaceutical company Boehringer Ingelheim recently presented encouraging data regarding its investigational drug tiotropium delivered through the company's Respimat inhaler, for the treatment of asthma. The data was presented … Tiotropium improves lung function in asthma, regardless of allergic status |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: Vapendavir; Drug: Vapendavir; Drug: Placebo
Sponsor: Biota Pharmaceuticals, Inc.
Recruiting – verified February 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function …
PR Newswire (press release) HOUSTON, Feb. 21, 2015 /PRNewswire/ — Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat® inhaler from five Phase III trials from the UniTinA-asthma® program at the 2015 American Academy of Allergy, … |
View full post on asthma – Google News